Answers are grounded in this paper and cite their sources.
MTX-related clinical neurotoxicity is transient, and most patients can receive subsequent MTX without recurrence of acute or subacute symptoms. All symptomatic patients and one in five asymptomatic patients develop leukoencephalopathy that can persist until the end of therapy. Polymorphisms in genes related to neurogenesis may contribute to susceptibility to MTX-related neurotoxicity.
No takes yet. Share an insight, caveat, or question.
Bhojwani et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: